

of the contemplated Exclusive Patent License. Comments and objections to this notice submitted will not be made available for public inspection and, to the extent permitted by law, will not be released under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: March 21, 2017.

Cristina Thalhammer-Reyero,

*Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.*

[FR Doc. 2017-06546 Filed 4-3-17; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Start-up Exclusive Evaluation Option Patent License: "The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans"

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Evaluation Option License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Tar Meta Biosciences, Inc. ("TarMeta") located in King of Prussia, PA, USA.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 19, 2017 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated Start-up Exclusive Evaluation Option License should be directed to: Kathleen Higinbotham, Senior Technology Transfer Manager, NCI Technology Transfer Center, Riverside 5, Suite 400, 8490 Progress Dr., Frederick, MD 21701, Telephone: (301)-624-8775; Facsimile: (301)-631-3027 Email: higinbok@mail.nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

(1) E-025-2010/0 entitled "Nitric Oxide-based Cancer Therapeutic Agents For Lung

Cancers With Elevated Levels Of Reactive Oxygen Species (ROS) And/or Low Levels Of Antioxidant Defense/DNA Repair Mechanisms."

(a) United States Provisional Patent Application No. 61/261,175 filed November 13, 2009;

(b) PCT Application No. PCT/US2010/056446 filed November 12, 2010;

(c) United States Patent Application No. 13/509,431 filed June 01, 2012, US Patent 9,205,091 issued December 08, 2015;

(d) Australian Patent Application No. 2010319398 filed May 09, 2012;

(e) Canadian Patent Application No. 2,780,633 filed May 10, 2012;

(f) European Patent Application No. 10778814.3 filed May 14, 2012;

(2) E-220-2011/0 entitled "Hybrid Diazeniumdiolated Compounds, Pharmaceutical Compositions, And Method Of Treating Cancer."

(a) United States Provisional Patent Application No. 61/549,862, filed October 21, 2011;

(b) PCT Application No. PCT/US2012/060785 filed October 18, 2012;

(c) United States Patent Application No. 14/352,096 filed April 16, 2014, US Patent 9,168,266 issued October 27, 2015;

(d) Australian Patent Application No. 2012326105 filed April 14, 2014;

(e) Canadian Patent Application No. 2,852,682 filed April 14, 2014;

(f) European Patent Application No. 12841601.3 filed April 14, 2014, European Patent 2768824 issued December 07, 2016;

(i) German Patent 602012026435.7 issued December 07, 2016;

(ii) French Patent 2768824 issued December 07, 2016; and

(iii) UK Patent 2768824 issued December 07, 2016.

The patent rights in these inventions have been assigned to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to "The development and use of diazeniumdiolated and hybrid diazeniumdiolated compounds for the treatment of ovarian cancer in humans."

The present inventions describe the use of diazeniumdiolate-based nitric oxide (NO)-releasing compounds wherein the cancer cell has an elevated level of reactive oxygen species (ROS), as well as the use of hybrid prodrug molecules that combine a diazeniumdiolated compound and a poly(ADP-ribose) polymerase (PARP) inhibitor in cancer cells to produce synergistic effects, whether alone or as an adjuvant for other therapies. The hybrid prodrug is expected to enhance cytotoxicity by creating DNA damage with NO and preventing its repair with the PARP inhibitor. The prodrug and the hybrid are activated by glutathione S-transferase and are predicted to be effective in cancers with reactive oxygen species (ROS), both of which are

elevated in many cancers. In addition, the prodrug and hybrid may have synergy with therapeutics (such as proteasome inhibitor bortezomib and doxorubicin) which act through generation of ROS. Taken together, these features suggest that the prodrug and hybrid may have therapeutic applications in cancer patients whose tumors include high levels of ROS.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective Start-up Exclusive Evaluation Option License will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Start-up Exclusive Evaluation Option License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: March 21, 2017.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2017-06545 Filed 4-3-17; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Molecular Mechanisms of Ventilator-Induced Lung Injury.

Date: April 27, 2017.

Time: 10:00 a.m. to 12:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Room 7206, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Shelley S Sehnert, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD 20892-7924, 301-435-0303, ssehnert@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: March 29, 2017.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-06551 Filed 4-3-17; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Frederick National Laboratory Advisory Committee to the National Cancer Institute.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will also be videocast and can be accessed from the NIH Videocasting and Podcasting Web site (<http://videocast.nih.gov/>).

Name of Committee: Frederick National Laboratory Advisory Committee to the National Cancer Institute.

Date: May 8, 2017.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: Ongoing and new activities at the Frederick National Laboratory for Cancer Research.

Place: National Institutes of Health, 31 Center Drive, Building 31, Wing C; 6th Floor, Conference Room 10, Bethesda, MD 20892.

Contact Person: Caron A. Lyman, Ph.D., Executive Secretary, National Cancer

Institute, National Institutes of Health, 9609 Medical Center Drive, Room 7W-126, Bethesda, MD 20892, 240-276-6348, lymanca@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/fac/fac.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 29, 2017.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-06550 Filed 4-3-17; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel, Developmental Programming and Aging.

Date: May 2, 2017.

Time: 12:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, Suite 2W200C, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Greg Bissonette, Ph.D., Scientific Review Officer, National Institute on Aging, National Institutes of Health, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-402-1622, bissonettegb@mail.nih.gov.

Name of Committee: National Institute on Aging Special Emphasis Panel, Translational Bioinformatics and Alzheimer's Disease.

Date: May 18, 2017.

Time: 12:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, Suite 2W200C, 7201 Wisconsin Ave., Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Greg Bissonette, Ph.D., Scientific Review Officer, National Institute on Aging, National Institutes of Health, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-402-1622, bissonettegb@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: March 29, 2017.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-06552 Filed 4-3-17; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG-2017-0203]

National Maritime Security Advisory Committee

AGENCY: Coast Guard, Department of Homeland Security.

ACTION: Notice of Federal Advisory Committee Meeting.

SUMMARY: The National Maritime Security Advisory Committee will meet in Norfolk, Virginia, to review and discuss various issues relating to national maritime security. All meetings will be open to the public.

DATES: The Committee will meet on Tuesday, April 25, 2017, from 12 Noon to 4:30 p.m. and on Wednesday, April 26, 2017, from 8 a.m. to 12 Noon. This meeting may close early if all business is finished.

ADDRESSES: The meeting will be held in the Port of Virginia Conference Room on the 6th floor of the World Trade Center,